...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Indium-111-Labelled Donor-Lymphocyte Infusion by way of Hepatic Artery and Radio-Frequency Ablation against Liver Metastases of Renal and Colon Carcinoma after Allogeneic Hematopoietic Stem-Cell Transplantation.
【24h】

Indium-111-Labelled Donor-Lymphocyte Infusion by way of Hepatic Artery and Radio-Frequency Ablation against Liver Metastases of Renal and Colon Carcinoma after Allogeneic Hematopoietic Stem-Cell Transplantation.

机译:异体造血干细胞移植后通过肝动脉输注铟111标记的供体淋巴细胞和射频消融肾和结肠癌的肝转移。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND.: In patients with metastatic solid cancer, antitumor effects occur after allogeneic stem-cell transplantation (SCT). However, this treatment is not as effective in the liver as against pulmonary and lymph-node metastases. To intensify the effect of donor-lymphocyte infusions (DLI) against liver metastases, intra-arterial (IA) cell injection by way of the hepatic artery (HA) can be used. METHODS.: To trace infused cells, three patients with colorectal, three with renal, and one with breast carcinoma were treated with Indium-111 (111-In)-oxinate-labeled lymphocytes. Four patients received the DLI IA, all after radio-frequency ablation (RFA) of liver metastases. Three patients with other metastases received 111-In DLI intravenously (IV). One of them had RFA before SCT. RESULTS.: Localization of the IA 111-In DLI activity on scintigrams homed to the liver. After IA injection, the liver to sternum ratio of radioactivity was higher compared with IV injection. Cells (CD3+, 19+, and 56+) of donor origin in biopsies of liver metastasis in two patients treated with IA injection increased to 80% to 100%. Two of four patients treated using the IA DLI showed stable size and number of liver metastases for 5 and 21 months, respectively. Both are alive 18 and 34 months after SCT. Two of three patients receiving DLI IV are doing well, with a stable metastatic disease or still without metastases 21 and 20 months after cell infusions (26 and 34 months after SCT), respectively. Three patients died because of progressive disease. CONCLUSION.: When infused by way of the HA, 111-In-labeled lymphocytes home to the liver and its metastases. The liver metastasis infiltrating cells of donor origin increased. DLI by way of the HA combined with RFA may be used to treat liver metastases after SCT.
机译:背景:在患有转移性实体癌的患者中,同种异体干细胞移植(SCT)后发生抗肿瘤作用。但是,这种治疗在肝脏中不如对肺和淋巴结转移有效。为了增强供体淋巴细胞输注(DLI)对肝转移的作用,可以使用通过肝动脉(HA)进行的动脉内(IA)细胞注射。方法:为追踪输注的细胞,对3例结直肠癌患者,3例肾癌患者和1例乳腺癌患者进行了铟111(In-oxinate)标记的淋巴细胞治疗。射频消融(RFA)肝转移后,四名患者均接受DLI IA。三名其他转移患者接受了静脉注射111-In DLI(IV)。其中一位在SCT之前接受过RFA。结果:IA 111-In DLI活性在归巢于肝脏的闪烁图上的定位。 IA注射后,肝脏与胸骨的放射活性比IV注射高。在接受IA注射治疗的两名患者中,肝转移活检中供体来源的细胞(CD3 +,19 +和56+)增加至80%至100%。使用IA DLI治疗的四名患者中有两名分别在5个月和21个月内显示出稳定的肝脏转移灶大小和数量。两者在SCT后分别存活18个月和34个月。在接受DLI IV的三名患者中,有两名表现良好,分别在细胞输注后21和20个月(SCT后26和34个月)有稳定的转移性疾病或仍然没有转移。三例患者因进行性疾病死亡。结论:当通过HA注入时,111 In标记的淋巴细胞归巢于肝脏及其转移。供体来源的肝转移浸润细胞增加。通过HA与RFA结合的DLI可用于治疗SCT后的肝转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号